Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial
Mayo Clinic
Mayo Clinic
Masonic Cancer Center, University of Minnesota
National Institutes of Health Clinical Center (CC)
Thomas Jefferson University
Roswell Park Cancer Institute
First Affiliated Hospital of Zhejiang University
National Institutes of Health Clinical Center (CC)
Stanford University
Memorial Sloan Kettering Cancer Center
Milton S. Hershey Medical Center
University of Chicago
Hackensack Meridian Health
Center for International Blood and Marrow Transplant Research